Literature DB >> 28273010

Post-Babesiosis Warm Autoimmune Hemolytic Anemia.

Ann E Woolley1, Mary W Montgomery1, William J Savage1, Maureen O Achebe1, Kathleen Dunford1, Sarah Villeda1, James H Maguire1, Francisco M Marty1.   

Abstract

Background Babesiosis, a tickborne zoonotic disease caused by intraerythrocytic protozoa of the genus babesia, is characterized by nonimmune hemolytic anemia that resolves with antimicrobial treatment and clearance of parasitemia. The development of warm-antibody autoimmune hemolytic anemia (also known as warm autoimmune hemolytic anemia [WAHA]) in patients with babesiosis has not previously been well described. Methods After the observation of sporadic cases of WAHA that occurred after treatment of patients for babesiosis, we conducted a retrospective cohort study of all the patients with babesiosis who were cared for at our center from January 2009 through June 2016. Data on covariates of interest were extracted from the medical records, including any hematologic complications that occurred within 3 months after the diagnosis and treatment of babesiosis. Results A total of 86 patients received a diagnosis of babesiosis during the 7.5-year study period; 18 of these patients were asplenic. WAHA developed in 6 patients 2 to 4 weeks after the diagnosis of babesiosis, by which time all the patients had had clinical and laboratory responses to antimicrobial treatment of babesiosis, including clearance of Babesia microti parasitemia. All 6 patients were asplenic (P<0.001) and had positive direct antiglobulin tests for IgG and complement component 3; warm autoantibodies were identified in all these patients. No alternative explanation for clinical hemolysis was found. WAHA required immunosuppressive treatment in 4 of the 6 patients. Conclusions We documented post-babesiosis WAHA in patients who did not have a history of autoimmunity; asplenic patients appeared to be particularly at risk.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28273010     DOI: 10.1056/NEJMoa1612165

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  8 in total

Review 1.  Babesia microti: from Mice to Ticks to an Increasing Number of Highly Susceptible Humans.

Authors:  Lars F Westblade; Matthew S Simon; Blaine A Mathison; Laura A Kirkman
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

2.  Hemagophagocytic lymphohistiocytosis associated with recurrent Babesiosis with Lyme disease co-infection in an immunocompromised host on anti-CD20 monoclonal antibody therapy: A case report.

Authors:  Aleena Zahra; Luis A Marcos
Journal:  IDCases       Date:  2022-07-13

Review 3.  Autoimmune Hemolytic Anemia Associated With Human Babesiosis.

Authors:  Pramuditha Rajapakse; Kamila Bakirhan
Journal:  J Hematol       Date:  2021-04-27

4.  Autoimmune hemolytic anemia associated with babesiosis.

Authors:  Roshni Narurkar; Aleksandra Mamorska-Dyga; John C Nelson; Delong Liu
Journal:  Biomark Res       Date:  2017-04-08

5.  Human Case Infected With Babesia venatorum: A 5-Year Follow-Up Study.

Authors:  Lin Zhao; Ruiruo Jiang; Na Jia; Nianzhi Ning; Yuanchun Zheng; Qiubo Huo; Yi Sun; Tingting Yuan; Baogui Jiang; Tao Li; Hongbo Liu; Xiong Liu; Yanli Chu; Ran Wei; Cai Bian; Hong Wang; Juliang Song; Hui Wang; Jiafu Jiang; Wuchun Cao
Journal:  Open Forum Infect Dis       Date:  2020-02-18       Impact factor: 3.835

6.  Serendipitous Finding of Asymptomatic Babesiosis in a Patient With Symptomatic Thrombocytopenia.

Authors:  Lalitha Anand; Morana Vojnic; Colette Spaccavento
Journal:  J Hematol (Brossard)       Date:  2019-12-25

7.  Babesiosis and the human immune system.

Authors:  Hussein Rabah; Divya Chukkalore; Elie El-Charabaty; Neville Mobarakai
Journal:  IDCases       Date:  2021-12-18

8.  Babesia microti-induced fulminant sepsis in an immunocompromised host: A case report and the case-specific literature review.

Authors:  Harry A Conte; Michael C Biondi; Sok-Ja Janket; Leland K Ackerson; Eleftherios P Diamandis
Journal:  Open Life Sci       Date:  2022-09-14       Impact factor: 1.311

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.